A Randomized, Open-Label, Two-Way Crossover, Single-Dose Bioequivalence Study of Temozolomide 200 mg/m 2 (Dralitem ® vs. Temodal ® Capsules) in Patients with Primary Tumors of the Central Nervous System Under Fasting Conditions
ConclusionsTemozolomide Dralitem® capsules, 20, 100 and 250 mg, were bioequivalent to Temodal® capsules under fasting conditions in patients with CNS primary tumors, supporting that they are therapeutic equivalents.ClinicalTrials.gov Identifier: NCT02343081.
Source: Drugs in R&D - Category: Drugs & Pharmacology Source Type: research
More News: Aphasia | Brain Tumor | Drugs & Pharmacology | Glioma | Lymphoma | Pain | Primary CNS Lymphoma | Study | Temodar